Angiotensin II antagonists – therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy

References

• McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998;56:847–69
   Google Scholar
• McClellan KJ, Balfour JA. Eprosartan. Drugs 1998;55:713–8
   PubMed Web of Science ®Google Scholar
• Markham A, Spencer CM, Jarvis B. Irbesartan: an updated review of its use in cardiovascular disorders. Drugs 2000;59:1187–206
   Google Scholar
• Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996;51:820–45
   PubMed Web of Science ®Google Scholar
• Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002;62:1345–53
   PubMed Web of Science ®Google Scholar
• Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001;61:1501–29
   Google Scholar
• Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54: 299–311
   Google Scholar
• Soffer BA, Wright Jr JT, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112–7
   PubMed Web of Science ®Google Scholar
• Dunlay MC, Fitzpatrick V, Chrysant S, et al. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens 1995;9:861–7
   PubMed Web of Science ®Google Scholar
• Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995;8:578–83
   PubMed Web of Science ®Google Scholar
• Reif M, White WB, Fagan TC, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1998;82:961–5
   PubMed Web of Science ®Google Scholar
• Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hyper-tension. J Hum Hypertens 1997;11(Suppl 2):S69–73
   PubMed Web of Science ®Google Scholar
• Sega R. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999;8:114–21
   Google Scholar
• Gradman AH, Gray J, Maggiacomo F, et al. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group. Clin Ther 1999;21:442–53
   Google Scholar
• Hedner T, Himmelmann A. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. J Hypertens 1999;17:129–36
   Google Scholar
• Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999;12:797–805
   PubMed Web of Science ®Google Scholar
• Larochelle P, Flack JM, Marbury TC, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am J Cardiol 1997;80:1613–5
   Web of Science ®Google Scholar
• Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252–9
   PubMed Web of Science ®Google Scholar
• Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001;24:641–6
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Martin K. Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am J Ther 2002;9:111–7
   Google Scholar
• Neutel JM, Klein C, Meinicke TW, et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002;11:302–9
   PubMed Web of Science ®Google Scholar
• Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998;12:861–6
   Google Scholar
• Cifkova R, Peleska J, Hradec J, et al. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens 1998;12:563–7
   PubMed Web of Science ®Google Scholar
• Chan P, Tomlinson B, Huang TY, et al. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997;37:253–7
   PubMed Web of Science ®Google Scholar
• Chan JC, Critchley JA, Lappe JT, et al. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995;9:765–71
   PubMedGoogle Scholar
• Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004;44:1175–80
   PubMed Web of Science ®Google Scholar
• Neldam S, Forsen B. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Drugs Aging 2001;18:225–32
   PubMed Web of Science ®Google Scholar
• Ruilope L, Jager B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press 2001;10:223–9
   Google Scholar
• de la Sierra SA, Munoz A, Arcos E, et al. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. Blood Press Suppl 2004;2:5–10
   PubMedGoogle Scholar
• Lacourciere Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged ≥ 65 years with mild to moderate hypertension. Clin Ther 2000;22:1213–24
   PubMed Web of Science ®Google Scholar
• Michel MC, Bohner H, Koster J, et al. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf 2004;27:335–44
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Zoppi A, et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004;59:863–8
   PubMed Web of Science ®Google Scholar
• Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged ≥ 65 years with systolic hypertension. Clin Ther 2000;22:961–9
   PubMed Web of Science ®Google Scholar
• Malacco E, Vari N, Capuano V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study. Clin Ther 2003;25:2765–80
   PubMed Web of Science ®Google Scholar
• Cushman WC, Brady WE, Gazdick LP, et al. The effect of a losartan-based treatment regimen on isolated systolic hypertension. J Clin Hypertens (Greenwich) 2002;4:101–7
   PubMedGoogle Scholar
• Farsang C, Garcia-Puig J, Niegowska J, et al. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. J Hypertens 2000;18:795–801
   Google Scholar
• Volpe M, Junren Z, Maxwell T, et al. Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther 2003;25:1469–89
   PubMed Web of Science ®Google Scholar
• Wing LM, Arnolda LF, Upton J, et al. Candesartan and hydrochlorothiazide in isolated systolic hypertension. Blood Press 2003;12:246–54
   PubMed Web of Science ®Google Scholar
• Weir MR, Weber MA, Neutel JM, et al. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens 2001;14:567–72
   PubMed Web of Science ®Google Scholar
• Manolis AJ, Reid JL, de Zeeuw D, et al. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. J Hypertens 2004;22:1033–7
   PubMed Web of Science ®Google Scholar
• Samra SS, Dongre N, Ballary C, et al. Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study. J Indian Med Assoc 2003;101:327–8
   PubMedGoogle Scholar
• Li Y, Liu G, Jiang B, et al. A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in Chinese patients with mild to moderate essential hypertension. Int J Clin Pract 2003;57:673–7
   PubMed Web of Science ®Google Scholar
• Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001;24:641–6
   PubMed Web of Science ®Google Scholar
• Flack JM, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001;23:1193–208
   PubMed Web of Science ®Google Scholar
• Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148–55
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Narayan P, Kokkinos P. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in African– American patients with hypertension. J Clin Hypertens (Greenwich) 2004;6:310–4
   Google Scholar
• Association of Black Cardiologists (ABC) Candesartan Study Group. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial. Heart Dis 2000;2:392–9
   Google Scholar
• Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin 1999;15:25–32
   PubMed Web of Science ®Google Scholar
• McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001;24:66–72
   PubMed Web of Science ®Google Scholar
• Weir MR, Smith DH, Neutel JM, et al. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens 2001;14:665–71
   PubMedGoogle Scholar
• Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152: 56–64
   Google Scholar
• McInnes GT. Systolic hypertension as a cardiovascular risk factor. Blood Press 2002;11:134–43
   PubMed Web of Science ®Google Scholar
• Black HR. The paradigm has shifted, to systolic blood pressure. Hypertension 1999;34:386–7
   PubMed Web of Science ®Google Scholar
• Deedwania PC. The changing face of hypertension: is systolic blood pressure the final answer? Arch Intern Med 2002;162: 506–8
   PubMed Web of Science ®Google Scholar
• Izzo Jr JL, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000;35:1021–4
   Google Scholar
• He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999;138:211–9
   PubMed Web of Science ®Google Scholar
• Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001;37: 869–74
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72
   PubMed Web of Science ®Google Scholar
• Ramsay L, Williams B, Johnston G, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569–92
   PubMed Web of Science ®Google Scholar
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21: 1011–53
   Google Scholar
• Stergiou GS. Angiotensin receptor blockade in the challenging era of systolic hypertension. J Hum Hypertens 2004;18:837–47
   PubMed Web of Science ®Google Scholar
• Swales JD. Current status of hypertensive disease treatment: results from the Evaluation and Interventions for Systolic Blood pressure Elevation: Regional and Global (EISBERG) project. J Hypertens Suppl 1999;17:S15–9
   Google Scholar
• Volpe M. Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists. J Hum Hypertens 2005;19:93–102
   PubMed Web of Science ®Google Scholar
• Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004;19;141:614–27
   Google Scholar
• Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 2004;43: 1047–55
   PubMed Web of Science ®Google Scholar
• Conlin PR. Redefining efficacy of antihypertensive therapies beyond blood pressure reduction – the role of angiotensin II antagonists. Int J Clin Pract 2005;59:214–24
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875–86
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022–31
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491–8
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–10
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Julius S, Hedner T, et al. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001;10:190–2
   PubMed Web of Science ®Google Scholar
• Dahlof B, Burke TA, Krobot K, et al. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004;18:367–73
   PubMed Web of Science ®Google Scholar
• Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456–62
   PubMed Web of Science ®Google Scholar
• Olsen MH, Wachtell K, Neland K, et al. Losartan but not atenolol reduces carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005;14:177–83
   PubMed Web of Science ®Google Scholar
• Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hyper-cholesterolemia. Circulation 2000;101:1586–93
   PubMed Web of Science ®Google Scholar
• Wachtell K, Hornestram B, Lehto M, et al. Cardiovascular mortality and morbidity in hypertensive patients with atrial fibrillation: the LIFE study. J Am Coll Cardiol 2005;45:705–11
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653–9
   PubMed Web of Science ®Google Scholar
• Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, et al. Effect of losartan on human platelet activation. J Hypertens 1999;17: 447–52
   Google Scholar
• Erdem Y, Usalan C, Haznedaroglu IC, et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999;12:1071–6
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004;64:2537–65
   PubMed Web of Science ®Google Scholar
• Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52–61
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial: Long-term blood pressure trends in 13 449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003;16:544–8
   PubMed Web of Science ®Google Scholar
• Weber M. The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens 2003;21(Suppl 6):S37–46
   Google Scholar
• McMurray JJ. Angiotensin inhibition in heart failure. J Renin Angiotensin Aldosterone Syst 2004;5(Suppl 1):S17–22
   PubMed Web of Science ®Google Scholar
• Adams KF, Jr. Pathophysiologic role of the renin-angiotensinaldosterone and sympathetic nervous systems in heart failure. Am J Health Syst Pharm 2004;61(Suppl 2):S4–13
   Google Scholar
• Cruden NL, Newby DE. Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both? Am J Cardiovasc Drugs 2004;4:345–53
   PubMedGoogle Scholar
• Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450–6
   PubMed Web of Science ®Google Scholar
• Doyle JC, Mottram DR, Stubbs H. Prescribing of ACE inhibitors for cardiovascular disorders in general practice. J Clin Pharm Ther 1998;23:133–6
   Google Scholar
• Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59:7–10
   PubMed Web of Science ®Google Scholar
• McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056–64
   PubMed Web of Science ®Google Scholar
• Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747–52
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582–7
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–66
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–6
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–81
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767–71
   PubMed Web of Science ®Google Scholar
• Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004;141:693–704
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173–8
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669–77
   Google Scholar
• Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821–8
   PubMedGoogle Scholar
• GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet 1994;343:1115–22
   Google Scholar
• Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80–5
   Google Scholar
• Ertl G, Hu K. Anti-ischemic potential of drugs related to the renin-angiotensin system. J Cardiovasc Pharmacol 2001;37 (Suppl 1):S11–20
   Google Scholar
• Solomon SD. Beyond remodeling: a new paradigm for angiotensin-converting enzyme inhibitors following myocardial infarction. J Cardiovasc Pharmacol 2001;37(Suppl 1):S31–4
   Google Scholar
• Abbate A, Biondi-Zoccai GG, Baldi A. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol 2002;193:145–53
   PubMed Web of Science ®Google Scholar
• Greenberg BH. Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials. J Card Fail 2002;8:S486–90
   Google Scholar
• Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993;88:2277–83
   Google Scholar
• Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752–60
   Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–906
   PubMed Web of Science ®Google Scholar
• Bakris G, Sica D, Ram V, et al. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens 2002;15:53–7
   PubMed Web of Science ®Google Scholar
• Deedwania PC. Hypertension and diabetes: new therapeutic options. Arch Intern Med 2000;160:1585–94
   PubMed Web of Science ®Google Scholar
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253–9
   Google Scholar
• Tight blood pressure control, and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–13
   Google Scholar
• Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997;20: 1576–81
   Google Scholar
• Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641–50
   PubMed Web of Science ®Google Scholar
• Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645–52
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Corradi L, et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999;13:47–53
   PubMed Web of Science ®Google Scholar
• Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46:1182–8
   PubMed Web of Science ®Google Scholar
• Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577–81
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Gherardi G, et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000;35:1155–65
   PubMed Web of Science ®Google Scholar
• Efficacy of atenolol, and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317: 713–20
   Google Scholar
• Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328:495
   PubMed Web of Science ®Google Scholar
• Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994;45:S150–5
   PubMedGoogle Scholar
• Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952–61
   PubMed Web of Science ®Google Scholar
• Taylor R. How larges studies may mislead: the HOPE study. Pract Diabetes Intl 2001;18:208–11
   Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;20;345:851–60
   Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 200;345:870–8
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861–9
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672–8
   PubMed Web of Science ®Google Scholar
• Leehey DJ, Singh AK, Alavi N, et al. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000;77:S93–8
   PubMed Web of Science ®Google Scholar
• Manley HJ. Role of angiotensin-converting-enzyme inhibition in patients with renal disease. Am J Health Syst Pharm 2000;57(Suppl 1):S12–8
   Google Scholar
• Remuzzi A, Perico N, Amuchastegui CS, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40–9
   PubMed Web of Science ®Google Scholar
• Esmatjes E, Flores L, Inigo P, et al. Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001;16(Suppl 1):90–3
   PubMedGoogle Scholar
• Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762–9
   PubMed Web of Science ®Google Scholar
• Fernandez-Andrade C, Russo D, Iversen B, et al. Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int Suppl 1998;68:S120–4
   Google Scholar
• del Castillo D, Campistol JM, Guirado L, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 1998;68:S135–9
   PubMedGoogle Scholar
• Gansevoort RT, de Zeeuw D, Shahinfar S, et al. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens Suppl 1994;12:S37–42
   Google Scholar
• Holdaas H, Hartmann A, Berg KJ, et al. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998;13:3096–102
   PubMed Web of Science ®Google Scholar
• Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol 2003;284:F863–9
   PubMed Web of Science ®Google Scholar
• Amuchastegui SC, Azzollini N, Mister M, et al. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998;9:1948–55
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system? Kidney Int 1994;45:861–7
   PubMed Web of Science ®Google Scholar
• Weinberg AJ, Zappe DH, Ashton M, et al. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 2004;24:340–5
   PubMed Web of Science ®Google Scholar
• Cupisti A, Rizza GM, D’Alessandro C, et al. Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. Biomed Pharmacother 2003;57:169–72
   Google Scholar
• Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 2005;11:1291–300
   Google Scholar
• Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117–24
   PubMed Web of Science ®Google Scholar
• Mimran A, Ribstein J, DuCailar G. Angiotensin II receptor antagonists and hypertension. Clin Exp Hypertens 1999;21: 847–58
   Google Scholar
• Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999;21:23–33
   PubMed Web of Science ®Google Scholar
• Mallion JM, Goldberg AI. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Blood Press Suppl 1996;2:82–6
   PubMedGoogle Scholar
• Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997;54:885–902
   Google Scholar
• Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004;26(Suppl A):A28–32
   Google Scholar
• Freytag F, Holwerda NJ, Karlberg BE, et al. Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Press 2002;11:173–81
   PubMed Web of Science ®Google Scholar
• Contreras F, de la Parte MA, Cabrera J, et al. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension. Am J Ther 2003;10:401–8
   PubMedGoogle Scholar
• Kyrmizakis DE, Papadakis CE, Liolios AD, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Arch Otolaryngol Head Neck Surg 2004;130: 1416–9
   PubMed Web of Science ®Google Scholar
• Sica DA, Black HR. Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? J Clin Hypertens.(Greenwich) 2002;4:375–80
   Google Scholar
• Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41–6
   PubMed Web of Science ®Google Scholar
• Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671–81
   PubMed Web of Science ®Google Scholar
• Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999;15(Suppl F): 26F–8
   Google Scholar
• Silverstein RL, Fenves AZ, Ram CV. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects. Postgrad Med 2004;116: 31–8, 41
   Google Scholar
• Sada T, Mizuno M. Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker. Nippon Yakurigaku Zasshi 2004;124:257–69
   PubMedGoogle Scholar
• Reid JL. Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? J Renin Angiotensin Aldosterone Syst 2005;6:15–24
   PubMed Web of Science ®Google Scholar